Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment

Abstract

Monotherapy with low dose thalidomide results in treatment responses in approximately 30% of patients with advanced MM. The response appears to be higher if thalidomide treatment is started after the first relapse or progression in comparison with the second relapse or progression.

Treatment toxicity is acceptable even with prolonged exposure to the drug.